If GLP1 agonist peptides are therapeutic in PD following SC administration, then it would be necessary for the peptide to undergo RMT across the BBB via the GLP1 receptor (GLP1R) expressed at the BBB. This evidence concerns the gene GLP1R and Parkinson disease.